Cite
HARVARD Citation
Fornecker, L. et al. (2023). Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. Journal of clinical oncology. 41 (2), pp. 327-335. [Online].